APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics
GET POWR RATINGS... FREE!
APRE Stock Price Chart Interactive Chart >
APRE Price/Volume Stats
| Current price | $0.50 | 52-week high | $2.21 |
| Prev. close | $0.50 | 52-week low | $0.30 |
| Day low | $0.47 | Volume | 168,899 |
| Day high | $0.50 | Avg. volume | 305,980 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.77 | Market Cap | 26.58M |
APREA THERAPEUTICS, INC. (APRE) Company Bio
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.
Latest APRE News From Around the Web
Below are the latest news stories about APREA THERAPEUTICS INC that investors may wish to consider to help them evaluate APRE as an investment opportunity.
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors SummitDOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023. Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will participate in a panel discussion entitl |
Aprea (APRE) Rises on Advancing Lead Drug to Clinical StudiesAprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors. |
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid TumorsDOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations. The Phase 1/2a clinical trial is a multi-center, open-label, dose-escal |
Aprea Therapeutics Inc. (NASDAQ:APRE) Shares Plunges -38.46% In A Week – But Can It Keep Rising?In last trading session, Aprea Therapeutics Inc. (NASDAQ:APRE) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.32 trading at -$0.06 or -15.79% at ring of the bell on the day assigns it a market valuation of $15.57M. That closing price of APRE’s stock is … Aprea Therapeutics Inc. (NASDAQ:APRE) Shares Plunges -38.46% In A Week – But Can It Keep Rising? Read More » |
Aprea Therapeutics Inc. (NASDAQ: APRE) Now Carries A 12-Month Price Target Of $3.00.Aprea Therapeutics Inc. (NASDAQ:APRE)’s traded shares stood at 0.56 million during the last session. At the last check today, the stock’s price was $0.41, to imply a decrease of -21.89% or -$0.11 in intraday trading. The APRE share’s 52-week high remains $5.00, putting it -1119.51% down since that peak but still an impressive -17.07% since … Aprea Therapeutics Inc. (NASDAQ: APRE) Now Carries A 12-Month Price Target Of $3.00. Read More » |
APRE Price Returns
| 1-mo | 51.06% |
| 3-mo | -26.47% |
| 6-mo | -47.37% |
| 1-year | -76.08% |
| 3-year | -98.70% |
| 5-year | N/A |
| YTD | 51.06% |
| 2022 | -88.47% |
| 2021 | -41.67% |
| 2020 | -89.28% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...